We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Metagenome Libraries to Be Screened for Enzymes

By Biotechdaily staff writers
Posted on 30 Sep 2004
Two biotech companies have announced a joint program to screen genomes of a wide variety of microorganisms in order to identify genes that produce enzymes that may have many different commercial applications.

BRAIN Biotechnology AG (Zwingenberg, Germany) will exploit its proprietary libraries and microbial resources for screening, and will deliver characterized developmental enzyme candidates and corresponding genes to Genencor (Palo Alton, CA, USA). More...
Genencor will evaluate the candidates and combine their knowledge base with internal capabilities to develop potential enzyme products.

Central to BRAIN's approach to discovery is its BioArchive, a comprehensive collection of molecularly characterised microorganisms stored in a ready-to-screen format and an ever growing number of "metagenome” libraries. These cloned DNA fragments represent the genomes of entire habitat-specific communities of microorganisms, more than 99% of which are generally uncultivable. They encode a wealth of novel enzymes and entire metabolic pathways.

The integration of Genencor's technology platforms--including gene discovery and functional genomics, molecular evolution and design, metabolic pathway engineering, human immunology, biomaterial production, and formulation delivery systems--is purported to allow the company to design and produce biotechnology products faster, better, and more successfully than with traditional approaches. Genencor has named its integrated technology platforms "i-biotech.” Genecor's current products are used in applications as diverse as removing stubborn stains from clothing, converting starch to the sweetener in soft drinks, stonewashing of blue jeans, and enhancing the nutritional value of grains and animal feed.
"We are happy to start a collaboration with a global leader in enzyme technology and together create product value,” said Dr. Jürgen Eck, CSO at BRAIN. "Our metagenome resources are also key to novel proprietary backbones for novel products. Our efforts and investments in building up our resource-portfolio increasingly pay off.”

"BRAIN's resources and technologies are an ideal extension of our internal natural isolate and genomic screening capabilities,” said Dr. Wolfgang Aehle, Genencor senior scientist.


Related Links:
BRAIN Biotechnology AG
Genecor

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.